Skip to main content
main-content

05-06-2018 | Kidney cancer | Video

CARMENA trial of cytoreductive nephrectomy in renal cell carcinoma

Arnaud Méjean presents the CARMENA trial findings, suggesting that cytoreductive nephrectomy may no longer be the standard of care for metastatic renal cell carcinoma in the era of sunitinib (4:21).

Funding for this video was provided in part by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

See the research in context now

with trial summaries, expert opinion and congress coverage

Image Credits